SIETES :: 93213 citas

Resultados de la búsqueda por ERUPCIÓN REFINAR BÚSQUEDA

1.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

2.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Mozley LH, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102593]

3.

Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. [Ref.ID 102549]

4.

Anónimo. FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer. U.S. Food and Drug Administration 2015:13 de julio. [Ref.ID 99504]

5.

Anónimo. Galantamine: atteintes cutanées graves. Prescrire 2015;35:105. [Ref.ID 98914]

6.

Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol 2015;135:745-52. [Ref.ID 98852]

7.

Anónimo. Gliptines: pemphigoïdes bulleuses. Prescrire 2014;34:829. [Ref.ID 98462]

8.

Anónimo. Ziprasidone (marketed as Geodon and generics): Drug Safety Communication - Rare but potentially fatal skin reactions. U.S. Food and Drug Administration 2014:11 de diciembre. [Ref.ID 98379]

9.

Anónimo. Sorafenib (Nexavar) for thyroid cancer. Med Lett Drugs Ther 2014;56:43-4. [Ref.ID 97918]

10.

Anónimo. FDA approves olodaterol for COPD. DIA Daily 2014:1 de agosto. [Ref.ID 97759]

11.

Anónimo. Advertisement medicine to treat chronic lymphocytic leukemia gets FDA approval. DIA Daily 2014:13 de febrero. [Ref.ID 97514]

12.

Anónimo. Simeprevir (Olysio) for chronic hepatitis C. Med Lett Drugs Ther 2014;56:1-2. [Ref.ID 97179]

13.

Zeuzem S, Soriano V, Asselah T, Bronowicki J-P, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan J-P, Böcher W-O, Mensa FJ. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;369:630-9. [Ref.ID 95982]

14.

Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6. [Ref.ID 95252]

15.

Anónimo. Combination treatment with telaprevir, peginterferon alfa and ribavirin: serious skin reactions. United States of America. WHO Drug Information 2013;27:14-5. [Ref.ID 95225]

16.

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a aystematic review. Ann Intern Med 2013;158:114-23. [Ref.ID 94775]

17.

Anónimo. Tianeptine: atteintes hépatiques, neurologiques, cutaneées, etc.. Prescrire 2012;32:516. [Ref.ID 93367]

18.

Anónimo. FDA approves Iclusig to treat two rare types of leukemia. U.S. Food and Drug Administration 2012:14 de diciembre. [Ref.ID 93283]

19.

Anónimo. Vandetanib: risk of fatal outcome. Canada. WHO Drug Information 2012;26:112. [Ref.ID 93056]

20.

Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012;68:21-8. [Ref.ID 92257]